Abstract
Vitamin D deficiency is inversely associated with blood pressure and is felt to contribute to the genesis and maintenance of hypertension. Although well demonstrated in animal studies, in many clinical studies the association between vitamin D status and blood pressure has not been consistently observed or else has been quite small. These discrepancies may relate in part to methodological differences including: patient selection, study size and duration, and, in the case of vitamin D repletion studies, differences in the vitamin D supplement used, its dose, and dosing intervals. Polymorphisms in genes regulating vitamin D activation and function may explain some of the observed inconsistencies as suggested by recent studies. The present review examines experimental and clinical studies bearing on the inverse association between blood pressure and vitamin D status and concludes that a new definition of vitamin D deficiency using additional biomarkers may better select patients with hypertension who will respond to vitamin D supplementation.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-Hydroxyvitamin D3-1α-hydroxylase. J Clin Endocrinol Metab. 2001;86:888–94.
Hollis BW, Wagner CL. The role of the parent compound Vitamin D with respect to metabolism and function: why clinical dose intervals can affect clinical outcomes. J Clin Endocrinol Metab. 2013;98:4619–28.
Rostand SG. Vitamin D, blood pressure, and African Americans: toward a unifying hypothesis. Clin J Am Soc Nephrol. 2010;5:1697–703.
Li YC. Vitamin D, receptor signaling in renal and cardiovascular protection. Semin Nephrol. 2013;33:433–47. This is a detailed study of the reno- and cardio-protective effects of VDR signaling. It covers issues that directly and indirectly affect blood pressure, atherosclerosis, renal fibrosis, and proteinuria.
Kong J, Qiao G, Zhang Z, et al. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int. 2008;74:1577–81.
Merke J, Hofman W, Goldschmidt D, et al. Demonstration of 1,25(OH)2 vitamin D3 receptors and action in vascular smooth muscles in vitro. Calcif Tissue Int. 1987;41:112–4.
Zehnder D, Bland R, Chana RS, et al. Synthesis of 1, 25-dihyroxyvitamin D3 by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol. 2002;13:621–9.
Wang Y, Borchert ML, DeLuca HF. Identification of the vitamin D receptor in various cells of the mouse. Kidney Int. 2012;81:993–1001.
Holick MF. The vitamin D epidemic and its health consequences. J Nutr. 2005;135:2739S–48S.
Zhu JG, Ochalek JT, Kaufmann M, et al. CYPR1 is a major, but not exclusive contributor to 25-hydroxyvitamin D production in vivo. PNAS. 2013;110:15650–5.
Kaseda R, Hosojima M, Sato H, et al. Role of megalin and cubilin in the metabolism of vitamin D3. Ther Apher Dial. 2011;15 Suppl 1:14–7.
Nykjaer A, Dragun D, Walther D, et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) Vitamin D3. Cell. 1999;96:507–15.
Nykjaer A, Fyfe JC, Kozyraki R, et al. Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D3. PNAS. 2001;98:13895–900.
Hewison M, Zehnder D, Bland R, et al. 1α-hydroxylase and the action of vitamin D. J Mol Endocrinol. 2000;25:141–8.
Holick MF. Bioavailability of vitamin D and its metabolites in Black and White adults. N Engl J Med. 2013;369:2047–8.
Li YC, Kong J, Wei M, et al. 25-dihyroxyvitamin D(3) is a negative endocrine regulator of the of the renin-angiotensin system. J Clin Invest. 2002;110:229–38.
Resnick LM, Muller EB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Int Med. 1986;105:649–54.
Weng S, Sprague JE, Oh J, et al. Vitamin D deficiency induces high blood pressure and accelerates atherosclerosis in mice. PLoS One. 2013;8(1):e4625. doi:10.1371/journal.pone.0054625.
Kruger IM, Kruger MC, Doak CM, et al. The association of 25(OH)D with blood pressure and carotid-radial pulse wave velocity in African women. PLoS One. 2013;8(1):e54554. doi:10.1371/journal.pone.0054554.
Giallauria F, Milaneschi Y, Tanake T, et al. Arterial stiffness and vitamin D levels: the Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2012;97:3717–23.
Wong MSK, Delansorne R, Man RYK, et al. Vitamin D derivatives reduce endothelium-dependent contractions in the aorta of spontaneously hypertensive rat. Am J Physiol Heart Circ. 2008;295:H289–96.
Tare M, Emmett SJ, Coleman HA, et al. Vitamin D insufficiency is associated with impaired vascular endothelial and smooth muscle function and hypertension in young rats. J Physiol. 2011;589:4777–86.
Campia U, Choucair WK, Bryant MB, et al. Reduced endothelium-dependent and –independent dilation of conductive arteries in African Americans. J Am Coll Cardiol. 2002;40:754–60.
Sache A, Wolf G. Angiotensin II-induced reactive oxygen species and the kidney. J Am Soc Nephrol. 2007;18:2439–46.
Freundlich M, Quiroz Y, Zhang Z, Zhang Y, et al. Suppression of renin-angiotensin expression in the kidney paricalcitol. Kidney Int. 2008;74:1394–402.
Andrukhova O, Slavic S, Riesen SC, et al. Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice. Mol Endocrinol. 2014;28:53–64.
Watson KE, Abrolat ML, Malone LL, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation. 1997;96:1755–60.
Hsu JJ, Tintut Y, Demer LL. Vitamin D and osteogenic differentiation in the artery wall. Clin J Am Soc Nephrol. 2008;3:1542–7.
Chiu KC, Chu A, Go VL, et al. Hypovitaminosis D is associated with insulin resistance and beta-cell dysfunction. Am J Clin Nutr. 2004;79:820–5.
Conchol M, Scragg R. 25-hydroxyvitamin D, insulin resistance and kidney function in the Third National Health and Nutrition Survey. Kidney Int. 2007;71:134–9.
Sugden JA, Davies JL, Witham MD, et al. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med. 2008;25:320–5.
Okamura M, Takano Y, Saito Y, et al. Induction of nephrin gene expression by selective cooperation of the retinoic acid receptor and the vitamin D receptor. Nephrol Dial Transplant. 2009;24:3006–12.
Zehnder D, Quinkler M, Eardley KS, et al. Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal fibrosis. Kidney Int. 2008;74:1343–53.
Kuhlmann A, Haas CS, Gross M-L, et al. 1,25 dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol. 2004;286:F526–33.
Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005;68:2823–8.
Schwarz U, Amannn K, Orth SR, et al. Effect of 1,25(OH)D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int. 1998;53:1696–705.
Zhang Y, Kong J, Deb DK, et al. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol. 2010;21:966–73.
Barker DJP, Osmond C, Golding J, et al. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. Br Med J. 1989;298:564–7.
Lee JM, Smith JR, Philipp BL, et al. Vitamin D deficiency in a healthy group of mothers and new born infants. Clin Pedatr (Phila). 2007;46:42–4.
Bowyer L, Catling-Paull C, Diamond T, et al. Vitamin D, PTH and calcium levels in pregnant women and their neonates. Clin Endocrinol. 2009;70:372–7.
Williams DM, Fraser A, Fraser WD, et al. Associations of maternal 25-hydroxyvitamin D in pregnancy with offspring cardiovascular risk factors in childhood and adolescence: findings from the Avon Longitudinal Study of Parents and Children. Heart. 2013;99:1849–56.
Lopes AAS, Port FK. The low birth weight hypothesis as a plausible explanation for black/white differences in hypertension, non-insulin dependent diabetes, and end-stage renal disease. Am J Kidney Dis. 1995;25:350–6.
Rostand SG, Cliver SP, Goldenberg RL. Racial disparities in the association of foetal growth retardation to childhood blood pressure. Nephrol Dial Transplant. 2005;20:1592–7.
Amri K, Freund N, Vilar J, et al. Adverse effects of hyperglycemia on kidney developments in rats: in vivo and in vitro studies. Diabetes. 1999;48:2240–5.
Mann JFE, Wieçek A, Bommer J, et al. Effects of parathyroidectomy on blood pressure in spontaneously hypertensive rats. Nephron. 1987;45:46–52.
Merke J, Lucas PA, Szabo A, et al. Hyperparathyroidism and abnormal calcitriol metabolism in the spontaneously hypertensive rat. Hypertension. 1989;13:233–42.
Thierry-Palmer M, Carlyle KS, Williams MD, et al. Plasma 25-hydroxyvitamin D concentrations are inversely associated with blood pressure of Dahl salt-sensitive rats. J Steroid Biochem Mol Biol. 1998;66:255–61.
Young EW, Morris CD, Holcomb S, et al. Regulation of parathyroid hormone and vitamin D in essential hypertension. Am J Hypertens. 1995;8:957–64.
Pfeifer M, Begerow B, Minne HW, et al. Effects of short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001;86:1633–7.
Saxena N, Gutiérrez OM. Fibroblast Growth Factor 23, vitamin D, and health disparities among African Americans with chronic kidney disease. Semin Nephrol. 2013;33:448–56.
de Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol. 2011;22:1603–9.
Kent ST, Howard G, Crosson WL, et al. The association of remotely-sensed outdoor temperature with blood pressure levels in REGARDS: a cross-sectional study of a large, national cohort of African-American and white participants. Environ Heal. 2011;10:7.
Godar DE, Pope SJ, Grant WB, et al. Solar UV doses of adult Americans and vitamin D3 production. Dermato-Endocrinol. 2011;3–4:243–50.
Reusch J, Ackermann H, Badenhoop K. Cyclical changes of vitamin D and PTH are primarily regulated by solar radiation: 5-year analysis of a German (50°N) population. Horm Metab Res. 2009;41:402–7.
Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension. 1997;30(Part 1):150–6.
Diffey BL. Solar ultraviolet radiation effects on biological systems. Phys Med Biol. 1991;36:299–328.
Cooper R, Rotimi C, Ataman S, et al. The prevalence of hypertension in seven populations of West African origin. Am J Public Health. 1997;87:160–8.
Holick MF. Photosynthesis of vitamin D in the skin; effect of environment and life-style variables. Fed Proc. 1987;46:1876–82.
Scragg R, Sowers M, Bell C. Serum 25-Hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens. 2007;20:713–9.
Krause R, Bühring M, Hopfenmuller W, et al. Ultraviolet B and blood pressure. Lancet. 1998;352:709–10.
Young JH, Chang Y-P, Kim JD-O, et al. Differential susceptibility to hypertension is due to selection during the Out of Africa expansion. PLoS Genet. 2005;1(6):e82. doi:10.1371/journal.pgen.0010082.
Opländer C, Volkmar CM, Paunel-Görgülü A, et al. Whole body UVA irradiation lowers systemic blood pressure by release of nitric oxide from intracutaneous photolabile nitric oxide derivatives. Circ Res. 2009;105:1031–40.
Liu D, Fernandez BO, Hamilton A, et al. UVA irradiation of human skin vasodilates arterial vasculature and lowers blood pressure independently of nitric oxide synthase. J Invest. Derm accepted article preview 2014. doi:10.1038/jid.2014.27.
Scragg R, Wishart J, Stewart A, et al. No effect of ultraviolet radiation on blood pressure and other cardiovascular risk factors. J Hypertens. 2011;28:1749–56.
Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension. 2007;49:1063–9.
Forman JP, Curhan GC, Taylor EN. Plasma 25-hydoxyvitamin D levels and risk of incident hypertension among young women. Hypertension. 2008;52:828–32.
De Boer IH, Katz R, Conchol M, et al. Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. Clin J Am Soc Nephrol. 2011;6:2141–9.
Ke L, Graubard BI, Albanes D, et al. Hypertension, pulse, and other cardiovascular risk factors and vitamin D status in Finnish men. Am J Hypertens. 2013;26:951–6.
Lind L, Hänni A, Lithell H, et al. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens. 1995;8:894–901.
Jorde R, Figenschau Y, Emaus N, et al. Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension. Hypertension. 2010;55:792–8.
Schmitz KJ, Skinner HG, Bautista LE, et al. Association of 25-hydroxyvitamin D with blood pressure in predominantly 25-hydroxyvitamin D deficient Hispanics and African Americans. Am J Hypertens. 2009;12:867–70.
Sakamoto R, Jaceldo-Siegl K, Haddad E, et al. Relationship of vitamin D levels to blood pressure in a bi-ethnic population. Nutr Metab Cardiovasc Dis. 2013;23:776–84.
Judd SE, Nanes MS, Ziegler TR, et al. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Survey. Am J Clin Nutr. 2008;87:136–41.
Dorjgochoo T, Shu XO, Xiang Y-B, et al. Circulating 25-hydroxyvitamin D levels in relation to blood pressure parameters and hypertension in the Shanghai Women’s and Men’s Health Studies. Br J Nutr. 2012;108:449–58.
Caro Y, Negrón V, Palacios C. Association between vitamin D levels and blood pressure in a group of Puerto Ricans. P R Health Sci J. 2012;31:123–9.
Snijder MB, Lips P, Seidell JC, et al. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men. J Intern Med. 2007;261:558–65.
Van Ballegooijian AJ, Kestenbaum B, Sachs MC, et al. Association of 25-hydroxyvitamain D and parathyroid hormone with incident hypertension. The multi-ethnic study of atherosclerosis. J Am Coll Cardiol. 2014. doi:10.1016/j.jacc.2014.01.012.
Bischoff-Ferrari HA, Dawson-Hughes B, Stöcklin E, et al. Oral supplementation with 25(OH)D3 versus Vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity. J Bone Miner Res. 2012;27:160–9.
Forman JP, Scott JB, Ng K, et al. Effect of vitamin supplementation on blood pressure in blacks. Hypertension. 2013;61:779–85. This study is important because it points out that blood pressure decreases progressively with increasing doses of cholecalciferol. As a result it suggests there are doses below which a response is likely not to be found or else will be very small.
Forman JP, Bischoff-Ferrari HA, Willett WC, et al. Vitamin D intake and risk of incident hypertension: results from three large prospective cohort studies. Hypertension. 2005;46:676–82.
Ng K, Scott JH, Drake BF, et al. Dose response to vitamin D supplementation in African-Americans; results of a 4-arm, randomized, placebo-controlled trial. Am J Clin Nutr. 2014. doi:10.3845/ajcn.113.067777.
Witham MD, Adams F, Kabir G, et al. Effect of short-term vitamin D supplementation on markers of vascular health in South Asian women living in the UK: a randomized controlled trial. Atherosclerosis. 2013;230:293–9.
Margolies KL, Ray RM, Van Horn L, et al. for the Women’s Health Initiative investigators. Effect of calcium and vitamin D supplementation on blood pressure: the Women’s Health Initiative Randomized Trial. Hypertension. 2008;52:847–55.
Kunutsor SK, Apekey TA, Steur M. Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants. Eur J Epidemiol. 2013;28:205–21. This meta-analysis covering a large number of patients concludes there is a small inverse association between blood pressure and 25-OHD concentrations.
Pilz S, Tomaschitz A, Ritz E, et al. Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol. 2009;6:621–30.
Manson JE, Bassuk SS, Lee I-M, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33:159–71.
Wang TJ, Richards JB, Kestenbaum B, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet. 2010;376:180–8. This paper discusses important single nucleotide polymorphisms at or near genes controlling enzymes regulating vitamin D metabolism, catabolism, and activation. Such polymorphisms are felt to identify those at increased risk for vitamin D deficiency. Unfortunately it does not discuss the relation of these gene polymorphisms to a possible interaction of vitamin D and blood pressure.
Kunutsor SK, Burgess S, Munroe PB, et al. Vitamin D and high blood pressure: causal association or epiphenomenon? Eur J Epidemiol. 2014;29:1–14. This GWAS/meta-analysis links blood pressure with polymorphisms in a gene controlling vitamin D metabolism, 1,25(OH)2D 24 hydroxylase (CYP24A1). Few other studies have looked for associations between blood pressure and gene polymorphisms related to vitamin D metabolism.
Wang L, Ma J, Buring JE, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor gene polymorphisms, and risk of hypertension in men. Eur J Nutr. 2013;52:1771–9.
Muray S, Parisi E, Cardús A, et al. Influence of vitamin D receptor gene polymorphisms on blood pressure in apparently healthy subjects. J Hypertens. 2003;21:2069–75.
Safadi FF, Thornton P, Magiera H, et al. Osteopathy and resistence to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest. 1999;103:239–51.
Powe CE, Evans MK, Wenger J, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med. 2013;369:1991–2000. This study finds racial differences in genetic polymorphisms for DBP. These findings account for differences in 25-OHD binding to DBP and to altered physiologic effectiveness of vitamin D as a result of changes in amounts of free to bound circulating 25OHD. It does not address the issue of blood pressure and vitamin D concentrations but, together with reference 88, it offers a possible explanation for the discrepant results noted in the many studies of vitamin D concentrations and vitamin D supplementation and blood pressure.
Acknowledgments
The author would like to thank Tilman Drueke, MD for his helpful comments and suggestions.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest Stephen G. Rostand declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Prevention of Hypertension: Public Health Challenges
Rights and permissions
About this article
Cite this article
Rostand, S.G. Vitamin D Deficiency in the Pathogenesis of Hypertension: Still an Unsettled Question. Curr Hypertens Rep 16, 464 (2014). https://doi.org/10.1007/s11906-014-0464-6
Published:
DOI: https://doi.org/10.1007/s11906-014-0464-6